# Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma

> **NCT07744750** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Changzhou No.2 People's Hospital** · enrollment: 40 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma
- Richter Transformation
- CLL / SLL
- MZL

## Interventions

- **DRUG:** Pirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma

## Key facts

- **NCT ID:** NCT07744750
- **Lead sponsor:** Changzhou No.2 People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-30
- **Primary completion:** 2027-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744750, "Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07744750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*